Martina Pagliuca

Benevento, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Abstracts of the 36th World Congress on Ultrasound in Obstetrics and Gynecology, 4-7 September 2026, London, UK.

Abstracts of the 36th World Congress on Ultrasound in Obstetrics and Gynecology, 4-7 September 2026, London, UK.

Journal: Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology

Published: July 06, 2026

Abstracts of the 36th World Congress on Ultrasound in Obstetrics and Gynecology, 4-7 September 2026, London, UK.

Abstracts of the 36th World Congress on Ultrasound in Obstetrics and Gynecology, 4-7 September 2026, London, UK.

Journal: Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology

Published: July 06, 2026

Development and validation of a predictive model of aromatase inhibitor-induced arthralgia among patients with early breast cancer.

Development and validation of a predictive model of aromatase inhibitor-induced arthralgia among patients with early breast cancer.

Journal: Journal of the National Cancer Institute

Published: May 05, 2026

CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety.

CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety.

Journal: Clinical breast cancer

Published: April 22, 2026

The long road after breast cancer: survivorship issues and long-term treatment effects in young women.

The long road after breast cancer: survivorship issues and long-term treatment effects in young women.

Journal: Frontiers in oncology

Published: March 27, 2026

Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials.

Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials.

Journal: Breast (Edinburgh, Scotland)

Published: March 19, 2026

Analysis of Large Language Model Decision Making in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Analysis of Large Language Model Decision Making in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Journal: JCO clinical cancer informatics

Published: March 06, 2026

Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis.

Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis.

Journal: Journal of the National Cancer Institute

Published: February 17, 2026

Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20-40 years.

Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20-40 years.

Journal: Breast (Edinburgh, Scotland)

Published: October 17, 2025

Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.

Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 20, 2025

ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors.

ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors.

Journal: Breast cancer research and treatment

Published: July 29, 2025

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Journal: EClinicalMedicine

Published: July 15, 2025

Showing 1-12 of 42

Last Updated: 09/26/2026